StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.40+0.40 (+2.22%)

Close on Nov 18, 2026Market cap $2.94BP/E –Yield –

Denali Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Denali Therapeutics's pe ratio was 141.2× on Jan 31, 2022.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jan 31, 2022141.2×−42.8
2021Dec 31, 2021184.1×–

More Denali Therapeutics figures

See a number that looks wrong?